Photobiomodulation Before Eccentric Fatigue Protocol in the Control of Pain and Muscle Damage Markers: A Double-Blind, Randomized Controlled Study.

Several strategies are used in the management of delayed-onset muscle soreness (DOMS), but there is not always evidence to justify its use. Photobiomodulation (PBM) is a noninvasive means, with promising previous results of its use in this outcome. This study aimed to identify the effects of PBM in the femoral quadriceps region to reduce DOMS in men undergoing a fatigue protocol. This is a double-blind, randomized controlled study. The sample consisted of 35 physically active men. The volunteers were divided into two groups: pre-fatigue PBM [Group 1 (G1)] and post-fatigue PMB [Group 2 (G2)]. The fatigue test was conducted at the same time of day. Given this was a crossover study of volunteers, we used at least a 1-week washout to avoid any residual interference from the previous intervention. PBM (active/placebo) was performed 5 min before the start of the fatigue protocol in G1 and immediately after the fatigue protocol in G2. PBM was applied at six points on the femoral quadriceps muscle (cluster laser/light emitting diodes 13, 415 mW, 30.2 J per point, 73 sec per application, and total dose of 181.2 J). In the data analysis, the primary endpoint was DOMS measured using a Numerical Pain Scale, and the secondary outcome was examined on the effects of PMB muscle damage, muscle contraction, and isometric horizontal jump. There were significant differences to PBM compared with the placebo group for DOMS, with no differences between the times of application. For muscle damage, there was significant difference ( > 0.05) when PBM was applied in pre-fatigue. G1 led to an increase of 14.9% in the creatine kinase level when active since the application of placebo PBM increased by 65% ( = 0.04). The PBM applied before eccentric fatigue protocol showed no significant results on DOMS, although there was a positive effect to control muscle damage. Brazilian Registry of Clinical Trials (RBR-7qhddz).